Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Abstract

The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I)wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

1 .- 23 . (canceled) 
     
     
         24 . A process for preparing a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, the process comprising mixing or blending the compound or the pharmaceutically acceptable salt with the pharmaceutically acceptable carrier to form the pharmaceutical composition. 
     
     
         25 . The process of  claim 24 , wherein the pharmaceutical composition is suitable for parenteral administration. 
     
     
         26 . The process of  claim 24 , wherein the pharmaceutical composition is suitable for injection. 
     
     
         27 . The process of  claim 24 , wherein the pharmaceutical composition is suitable for intravenous administration. 
     
     
         28 . The process of  claim 24 , wherein the pharmaceutical composition is suitable for oral administration. 
     
     
         29 . The process of  claim 24 , wherein the pharmaceutical composition contains from about 0.1 to about 95% by weight of the compound or the pharmaceutically acceptable salt. 
     
     
         30 . The process of  claim 24 , wherein the pharmaceutical composition contains from about 5 to about 70% by weight of the compound or the pharmaceutically acceptable salt. 
     
     
         31 . The process of  claim 24 , wherein the pharmaceutical composition contains from about 10 to about 60% by weight of the compound or the pharmaceutically acceptable salt. 
     
     
         32 . The process of  claim 24 , wherein the pharmaceutical composition is an aqueous solution. 
     
     
         33 . The process of  claim 32 , wherein the process further comprises adjusting the pH of the aqueous solution to about 4±0.5. 
     
     
         34 . The process of  claim 24 , wherein the pharmaceutical composition is a solid dosage form. 
     
     
         35 . The process of  claim 34 , wherein the process further comprises shaping or loading the pharmaceutical composition to form a unit dosage form. 
     
     
         36 . The process of  claim 35 , wherein the unit dosage form is a capsule, tablet or